Cardiology overview heart failure: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 10: | Line 10: | ||
===Lasix=== | ===Lasix=== | ||
*Higher lasix doses are associated with higher mortality, likely as a surrogate of disease severity rather than part of a causal pathway. | *Higher lasix doses are associated with higher mortality, likely as a surrogate of disease severity rather than part of a causal pathway. | ||
===Digoxin=== | |||
* [[Digoxin]] has not been associated with improvement in survival. It has been associated with a reduction in rehospitalization. In the DIG trial, the most effective and safest levels of digoxin were levels less than 1 ng/mL. levels greater than 1 ng/ml were no more effective and were associated with a trend towards higher mortality. | |||
===Beta Blockers=== | ===Beta Blockers=== | ||
| Line 23: | Line 26: | ||
* [[Dronedarone]] should be avoided in patients who were hospitalized with CHF (this is a boxed warning) | * [[Dronedarone]] should be avoided in patients who were hospitalized with CHF (this is a boxed warning) | ||
* [[Sotalol]] (has a negative inotropic effect) | * [[Sotalol]] (has a negative inotropic effect) | ||
==Mechanical Therapy== | ==Mechanical Therapy== | ||
Revision as of 17:41, 31 October 2011
|
Cardiology Overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Pharmacotherapy
Angiotensin Converting Enzyme (ACE) Inhibition
- Improve LV remodeling following ST elevation MI
- Even in patients who are asymptomatic with LV dysfunction, this class improves the odds of developing symptoms and survival.
Lasix
- Higher lasix doses are associated with higher mortality, likely as a surrogate of disease severity rather than part of a causal pathway.
Digoxin
- Digoxin has not been associated with improvement in survival. It has been associated with a reduction in rehospitalization. In the DIG trial, the most effective and safest levels of digoxin were levels less than 1 ng/mL. levels greater than 1 ng/ml were no more effective and were associated with a trend towards higher mortality.
Beta Blockers
Lopressor should be used instead of atenolol in the patient with CHF
Metformin
Enoxaparin and Antiocagulation
- While hospitalized, patients with CHF should receive DVT prophylaxis
Drugs to Avoid in CHF
- Dronedarone should be avoided in patients who were hospitalized with CHF (this is a boxed warning)
- Sotalol (has a negative inotropic effect)
Mechanical Therapy
- Cardiac resynchronization therapy has been associated with improvement in symptoms and a reduction in hospitalizations.
Ultrafiltration
- Ultrafiltration has been associated with a reduced incidence of hospitalization compared with diuretics in the UNLOAD trial. There was no difference in mortality.
Invasive Monitoring
- Based upon the results of the ESCAPE trial, there is no benefit in clinical outcomes with the use of a pulmonary artery line in patients with decompensated CHF.
Obstructive Sleep Apnea in the Patient with CHF
- Central sleep apnea in the patient with CHF is due to the compensatory respiratory alkalosis that is present in the patient with CHF and tachypnea